文献速递妇科

子宫内膜异位症药物治疗对骨骼健康的影响:系统综述与荟萃分析

Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2026-03-19

该系统综述与荟萃分析检索至2025年7月的文献,纳入37项研究,评估子宫内膜异位症激素治疗对育龄女性骨密度的影响。结果显示GnRH激动剂、地诺孕素和GnRH拮抗剂使用后骨密度下降,各药物效应不同,临床意义尚不确定。

要点

  • GnRH激动剂使用6个月和12个月时骨密度分别下降0.89%和1.50%。
  • 地诺孕素使用6个月和12个月时骨密度分别下降0.83%和1.91%,异质性高。
  • GnRH拮抗剂使用6个月时骨密度下降2.17%,多数研究缺乏反向添加治疗。

核心结论

  • 子宫内膜异位症的激素抑制治疗在12个月后与骨密度下降相关,每种药物效应独特,临床意义尚不确定。

研究设计与样本

  • 系统综述与荟萃分析,检索电子数据库至2025年7月,筛选1153项研究,最终纳入37项随机对照试验、前瞻性和回顾性队列研究,对象为育龄女性。

主要发现

  • GnRH激动剂汇总分析显示6个月骨密度下降-0.89%(95%CI -1.45至-0.33,I2=20.3%,11项研究),12个月下降-1.50%(95%CI -2.68至-0.31,I2=40.5%,4项研究)。
  • 亚组分析显示6个月时亮丙瑞林降低骨密度-1.33%(95%CI -1.92至-0.74,I2=0%,6项研究),戈舍瑞林降低-0.42%(95%CI -1.00至0.16,I2=11%,5项研究),均联合反向添加。
  • 地诺孕素与6个月骨密度降低-0.83%(95%CI -1.52至-0.15,I2=76.8%,6项研究)和12个月降低-1.91%(95%CI -2.58至-1.24,I2=83.7%,4项研究)相关,但异质性高。
  • GnRH拮抗剂6个月时降低骨密度-2.17%(95%CI -3.44至-0.90,I2=97.3%,5项研究),多数研究缺乏反向添加治疗。
  • 关于DMPA的4项研究数据无法进行荟萃分析。

临床怎么用

  • 对长期使用激素抑制治疗的子宫内膜异位症患者,应关注骨密度变化,尤其使用GnRH激动剂、地诺孕素或GnRH拮抗剂者。

局限性

  • 部分药物研究异质性高,DMPA数据无法荟萃分析,骨密度下降的临床意义尚不确定,需专家共识指导骨健康管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of endometriosis medical therapies on bone mineral density (BMD). DATA SOURCES: Electronic databases were searched from inception to July 2025 for clinical studies reporting the effect of hormonal treatments for endometriosis on BMD. METHODS OF STUDY SELECTION: Eligible studies included randomized controlled trials (RCTs) and prospective and retrospective cohort studies involving women of reproductive age. Interventions assessed were gonadotropin-releasing hormone (GnRH) agonists with add-back therapy, dienogest, GnRH antagonists, and depot medroxyprogesterone acetate (DMPA). Risk of bias was evaluated with the Cochrane Risk of Bias Tool to evaluate RCTs, the Risk of Bias in Non-Randomized Studies of Interventions tool for nonrandomized trials, and the Newcastle-Ottawa Scale for cohort studies. A total of 1,153 studies were screened, of which 37 met inclusion criteria. TABULATION, INTEGRATION, AND RESULTS: Pooled analysis of GnRH agonist showed a decrease in BMD at 6 months (-0.89%, 95% CI, -1.45 to -0.33, I2 =20.3%, 11 studies) and at 12 months (-1.50%, 95% CI, -2.68 to -0.31, I2 =40.5%, four studies). Subgroup analysis by GnRH agonist type decreased heterogeneity and showed that at 6 months both leuprolide (-1.33%, 95% CI, -1.92 to -0.74, I2 =0%, six studies) and goserelin (-0.42%, 95% CI, -1.00 to 0.16, I2 =11%, five studies) with add-back decreased BMD. Dienogest was associated with lower BMD at 6 months (-0.83%, 95% CI, -1.52 to -0.15, I2 =76.8%, six studies) and 12 months (-1.91%, 95% CI, -2.58 to -1.24. I2 =83.7%, four studies); however, there were high heterogeneity and inconsistency between studies. GnRH antagonist decreased BMD at 6 months (-2.17%, 95% CI, -3.44 to -0.90, I2 =97.3%, five studies), although most studies lacked add-back therapy. Data from four studies on DMPA could not be meta-analyzed. Risk of bias was low in studies included in the analysis. CONCLUSION: Hormonal suppression for endometriosis treatment is associated with a decrease in BMD after 12 months of use, with each medical therapy having a unique effect. The clinical significance of these findings remains uncertain, highlighting the need for expert consensus for bone health management in patients on long-term hormonal therapy. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42024580675.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Desilets J, Lakabi R, Olsthoorn A, et al. Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026. PMID: 41855532. doi:10.1097/AOG.0000000000006241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。